Skip to content
Screener

Nektar Therapeutics NKTR Cash & Equivalents

Cash & Equivalents at other companies

Amgen logo
AmgenAMGN
$574M+5.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.47B+22.3%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$205.19M+238%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$451.8M+323%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
$301.92M+944%
CTO
Citius Oncology, Inc.CTOR
$2.63M+2,350,466%

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.48B+539%
Enterprise value$2.56B+435%
P/S44.6×+39.4×

Profitability

See full
Gross margin100%+31.2pp
Operating margin-242%
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Cash.

The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.

Filed
May 7, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-212596
Line itemFair Value Hierarchy LevelMarch 31, 2026 / Amortized CostMarch 31, 2026 / Gross Unrealized GainsMarch 31, 2026 / Gross Unrealized LossesMarch 31, 2026 / Fair ValueDecember 31, 2025 / Fair Value
Corporate notes and bonds2$288,887$2$(723)$288,166$59,785
Corporate commercial paper2401,8161(307)401,510156,714
Obligations of U.S. government agencies24,490(7)4,483
Available-for-sale investments$695,193$3$(1,037)$694,159$216,499
Money market funds117,71011,919
Certificates of deposit214,02914,138
CashN/A5,6993,196
Total cash and investments in marketable securities$731,597$245,752

Item 1. Condensed Consolidated Financial Statements—Unaudited:

FAQ

What is Nektar Therapeutics's cash & equivalents?
Nektar Therapeutics (NKTR) reported cash & equivalents of $5.7M in Q1 2026.
How has Nektar Therapeutics's cash & equivalents changed year-over-year?
Nektar Therapeutics's cash & equivalents decreased by 20.0% year-over-year, from $7.12M to $5.7M.
What is the long-term trend for Nektar Therapeutics's cash & equivalents?
Over 5 years (2020 to 2025), Nektar Therapeutics's cash & equivalents has grown at a -12.7% compound annual growth rate (CAGR), from $6.29M to $3.2M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Nektar Therapeutics's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude